LETTER
Iloprost Availability
R. Garth McBride, MD
1 September 1994 | Volume 121 Issue 5 | Page 389
TO THE EDITOR:
We are indebted to the patients and investigators who participated in the study of intravenous iloprost in the treatment of Raynaud phenomenon secondary to systemic sclerosis [1]. Although an intravenous form of iloprost is marketed in most European countries, Berlex Laboratories will not pursue further development of this form in the United States. The considerable additional development work needed to support approval for marketing this treatment in the United States will instead be devoted to developing the data necessary to support oral administration of iloprost.
1. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994; 120:199-206.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
Reference
Article
